Growth Hormone Deficiency eBook
Focus on Growth Hormone.indd
Read More
Author: Rebecca Shover
Health and Safety at ASCO GU 2022
Individual Accountability ASCO is committed to maintaining the health and safety of all ASCO Genitourinary Cancers Symposium attendees. We will be reviewing the latest Centers for Disease Control and Prevention and World Health...
Read More
ASCO GU Program Guide 2022
Thursday, Feb 17: Exhibits Open 10:00 AM – 9:45 PM EST Novel Treatment Implementation: Prostate-Specific Membrane Antigen Targeting and Beyond Primary Track: Prostate Cancer 10:45 AM – 12:30 PM EST Optimizing Management of...
Read MoreASCO GU 2022 Is Here!
Program at a Glance • Highly interactive sessions with multidisciplinary perspectives on new, innovative findings in the study, diagnosis, and treatment of GU malignancies. • Presentation of the latest novel science and...
Read More
Dr. MedLaw Q&A: Addressing Intellectual Property
Q: I’m a pediatrician and my wife is a software designer. We were talking about combining these to...
Read More
Dr. MedLaw Q&A: The Legal Doctrine of Intervening Superseding Cause
Q: The rule at our ASU is that a patient who received sedation should not drive after discharge,...
Read More
Prescribe An App
“Eating right and exercising is hard. Can’t you prescribe an app for...
Read More
How to Ensure That Your Practice Complies With New Stark Regulation Clarifications
As of January 1 new Stark regulation clarifications are in effect, addressing the relationship...
Read More
Delivering Healthcare With Fewer People
Healthcare is experiencing yet another crisis – one of many that have unfolded over the past...
Read More
Female Physicians Still Earning Less Than Male Counterparts
Female physicians continue to find that they receive lower compensation than their male...
Read More
Take Our ASOPRS Quiz!
The ASOPRS 2022 PhysQuiz was created by the editorial staff at Physician’s Weekly. The ASOPRS 2022...
Read More
Assessing Treatment Options for Cystic Fibrosis Chronic Rhinosinusitis
“Nearly all individuals with cystic fibrosis (CF) suffer from chronic rhinosinusitis (CRS),” notes...
Read More
Designing Innovative Practice Spaces
“What are your goals?” is the first question Catherine Erikson asks physicians when helping them...
Read MorePhase 3 GLOW: first-line ibrutinib plus venetoclax improves outcomes in elderly or unfit CLL
With an updated median follow-up of 34.1 months, the 30-month progression-free survival (PFS) was 80.5% with ibrutinib plus venetoclax versus 35.8% for chlorambucil plus obinutuzumab in elderly or unfit patients with chronic...
Read MoreCAPTIVATE: Ibrutinib plus venetoclax show stunning efficacy in CLL
The first-line, chemotherapy-free regimen of ibrutinib plus venetoclax showed ongoing efficacy after 2 years of follow-up in patients with chronic lymphocytic leukemia (CLL). Patients with confirmed undetected Minimal Residual...
Read More
Subgroup analyses demonstrate consistent OS benefit of ribociclib in patients with locally advanced/metastatic HR-positive/HER2-negative breast cancer
In three MONALEESA phase 3 trials, addition of ribociclib to adjuvant endocrine therapy improved...
Read More
Elacestrant may improve outcomes for patients whose metastatic breast cancer progressed on prior endocrine therapy
According to the first results of the EMERALD trial, elacestrant, the first oral selective...
Read More
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab robustly benefits EFS in patients with early triple-negative breast cancer
Primary analysis of the KEYNOTE-522 trial shows a statistically significant and clinically...
Read More